Sherman Asset Management Inc. purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,249 shares of the exchange traded fund’s stock, valued at approximately $653,000. SPDR S&P Biotech ETF comprises 0.6% of Sherman Asset Management Inc.’s investment portfolio, making the stock its 29th largest position.
Several other hedge funds have also made changes to their positions in the stock. Garda Capital Partners LP bought a new stake in SPDR S&P Biotech ETF during the 4th quarter valued at $1,295,000. Flputnam Investment Management Co. raised its stake in SPDR S&P Biotech ETF by 86.1% during the 4th quarter. Flputnam Investment Management Co. now owns 40,113 shares of the exchange traded fund’s stock valued at $3,613,000 after acquiring an additional 18,555 shares in the last quarter. Proficio Capital Partners LLC raised its stake in SPDR S&P Biotech ETF by 16,156.1% during the 4th quarter. Proficio Capital Partners LLC now owns 917,329 shares of the exchange traded fund’s stock valued at $82,615,000 after acquiring an additional 911,686 shares in the last quarter. Kovack Advisors Inc. raised its stake in SPDR S&P Biotech ETF by 35.1% during the 4th quarter. Kovack Advisors Inc. now owns 6,146 shares of the exchange traded fund’s stock valued at $553,000 after acquiring an additional 1,597 shares in the last quarter. Finally, K.J. Harrison & Partners Inc raised its stake in SPDR S&P Biotech ETF by 9.2% during the 4th quarter. K.J. Harrison & Partners Inc now owns 23,800 shares of the exchange traded fund’s stock valued at $2,178,000 after acquiring an additional 2,000 shares in the last quarter.
SPDR S&P Biotech ETF Price Performance
Shares of SPDR S&P Biotech ETF stock opened at $88.71 on Friday. The business’s fifty day moving average price is $91.00 and its two-hundred day moving average price is $95.75. The company has a market capitalization of $5.85 billion, a P/E ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a 1-year low of $81.14 and a 1-year high of $105.47.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- How to Use the MarketBeat Dividend Calculator
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- What is the Nasdaq? Complete Overview with History
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- What Investors Need to Know to Beat the Market
- MarketBeat Week in Review – 02/24 – 02/28
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.